
Sign up to save your podcasts
Or


The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By POLITICO4.2
386386 ratings
The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports.
Learn more about your ad choices. Visit megaphone.fm/adchoices

25,942 Listeners

4,085 Listeners

1,365 Listeners

609 Listeners

1,508 Listeners

454 Listeners

701 Listeners

6,314 Listeners

963 Listeners

307 Listeners

107 Listeners

206 Listeners

7,255 Listeners

2,416 Listeners

5,482 Listeners

6,096 Listeners

136 Listeners

5,556 Listeners

32 Listeners

16,266 Listeners

715 Listeners

10 Listeners